Optimi Health Corp. closed an oversubscribed public offering, issuing 2,400,000 common shares at US$6.25 per share for aggregate gross proceeds of US$15,000,000 before underwriting discounts and offering expenses. The company’s common shares began trading on the Nasdaq Capital Market on May 20, 2026, under the symbol “OPTH,” and continue trading on the Canadian Securities Exchange under the symbol “OPTI.”
Company Focus and Expansion
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, the company produces validated MDMA and botanical psilocybin drug products at GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
Financing Terms
Joseph Gunnar & Co., LLC acted as sole book-running manager for the offering under an underwriting agreement dated May 19, 2026. The company granted 96,000 non-transferable common share purchase warrants to the underwriter, entitling it to purchase up to 96,000 common shares at US$7.50 per share until May 21, 2031. All securities issued were free from resale restrictions under applicable Canadian and United States securities laws. A registration statement on Form F-1 related to the offering was declared effective by the SEC on May 19, 2026.
Chief Executive Officer Dane Stevens stated that the financing “provides significant strength to our balance sheet and represents the necessary working capital for the growth of our business, with ample runway to scale over the next few years,” noting the company welcomed “a number of new, high-quality investors to our Nasdaq listing, who also see the benefits of psychedelic medicine.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/optimi-health-announces-closing-of-oversubscribed-us-15-million-public-offering